Table 4 Recommendations for antifungal prophylaxis in patients with ALL, CLL, NHL, HL and MM.

From: Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL)

Population

Intervention

SoR

QoE

ECIL 5-6

ALL

TKIs

Any prophylaxis

D

III

No data

Chemotherapy including vincristine

posaconazole voriconazole

D

II

Against

isavuconazole 200 mg q8h p.o. first 2 days then 200 mg q24h

C

III

No data

Fluconazole 400 mg q24h, p.o. or i.v.

C

III

C-III

CLL

Conventional treatment

Any prophylaxis

D

III

No recommendation

Refractory treated BTKIs and/or venetoclax

Mold-active prophylaxis

C

II

No recommendation

NHL

Treated with chemotherapy

Any prophylaxis

D

II

No recommendation

Refractory treated BTKIs or high doses steroids

Mold-active prophylaxis

C

II

No recommendation

Treated with

Bispecific antibodies

Any prophylaxis

D

II

No data

HL

Treated with chemotherapy

Any prophylaxis

D

II

No recommendation

MM

Treated with IMiDs

Any prophylaxis

D

II

No recommendation

Treated with

Bispecific antibodies

Any prophylaxis

D

II

No data

  1. ALL Acute Lymphoblastic Leukemia, CLL Chronic Lymphocytic Leukemia, NHL non-Hodgkin’s Lymphoma, HL Hodgkin’s Lymphoma, MM Multiple Myeloma, BTKIs Bruton tyrosine kinase inhibitors; IMiDs immunomodulatory drugs.
Back to article page